AZD6765

DRUG8 trials

Sponsors

AstraZeneca

Conditions

DepressionHealthyMajor Depressive DisorderTreatment Resistant Major Depressive Disorder

Phase 1

AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects

CompletedNCT00785915

AstraZenecaHealthy

Start: 2008-11-30End: 2009-03-31Updated: 2014-10-13

AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose (SAD/MAD)

WithdrawnNCT00963365

AstraZenecaHealthy

Start: 2008-11-30End: 2010-03-31Updated: 2014-10-13

Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects

CompletedNCT01046630

AstraZenecaDepression

Start: 2009-12-31End: 2011-03-31Updated: 2014-10-13

A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood Levels

CompletedNCT01069822

AstraZenecaHealthy

Start: 2010-02-28End: 2010-05-31Updated: 2014-10-13

A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765

TerminatedNCT01130909

AstraZenecaHealthy

Start: 2010-05-31End: 2011-01-31Updated: 2014-10-13

Phase 2

AZD6765 for Treatment Resistant Depression

CompletedNCT00491686

AstraZenecaDepression

Start: 2007-07-31End: 2007-11-30Updated: 2011-01-21

AZD6765 Severe Major Depressive Disorder (MDD) IV

CompletedNCT00781742

AstraZenecaMajor Depressive Disorder

Start: 2008-10-31End: 2010-03-31Updated: 2012-07-25

This is a Study to Determine the Antidepressant Effects of AZD6765

CompletedNCT00986479

AstraZenecaTreatment Resistant Major Depressive Disorder

Start: 2009-12-31End: 2011-12-31Updated: 2014-10-21

Related Papers

Population pharmacokinetic analysis of lanicemine (AZD6765), an NMDA channel blocker, in healthy subjects and patients with major depressive disorder.

2017-05-046 citations

Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate

European Neuropsychopharmacology2016-04-30113 citations